Draupnir Bio is a spin out company, from Aarhus University and the Max-Planck Society and establishing itself at the forefront of protein degradation.
Targeted protein degradation is an emerging therapeutic modality with the potential to tackle disease-causing proteins that have historically been highly challenging to target with conventional therapies. While proteolysis-targeting chimera (PROTAC) protein degraders have revolutionised the field of targeted protein degradation, it is limited to intracellular disease proteins.
Draupnir’s novel and proprietary platform technology is enabling the development of protein degraders that target extracellular disease proteins, with potential to target 40% of the human proteome and offering broad disease applicability across multiple areas of unmet therapeutic need. Through this differentiated platform technology, the company is building a broad pipeline of oral small molecule degraders of extracellular pathogenic proteins.